Published January 4, 2010 | Version Supplemental Material
Journal Article Open

Stereoselective Phosphine-Catalyzed Synthesis of Highly Functionalized Diquinanes

  • 1. ROR icon Massachusetts Institute of Technology

Abstract

Two rings to rule them all: A versatile method has been developed for the room‐temperature synthesis of diquinanes from acyclic precursors, thereby generating two rings, three stereocenters, and a double bond with high selectivity. The products of the double cyclization can be derivatized with excellent diastereoselection into an array of highly functionalized compounds. [reaction image] In 2003, Tomika and co‐workers reported an intriguing PnBu3‐catalyzed diastereoselective cyclization of certain yne‐diones to form bicyclic furanones with two new stereocenters (Figure 1).1 They proposed that conjugate addition of the phosphine to the alkyne is followed by tautomerization, which furnishes zwitterionic enolate A. Next, an intramolecular aldol reaction provides B, and then a second conjugate addition generates bicycle C (the conversion of A into C by a concerted cycloaddition may also be considered). Tautomerization and then elimination of the phosphine affords the bicyclic furanone. The investigation by Tomita et al. focused mainly on symmetrical substrates (R1=-C≡CR), although they did report reactions of two unsymmetrical yne‐diones which cyclized in relatively modest yield (41–50 %).

Additional Information

© 2010 WILEY‐VCH Verlag GmbH & Co. Received: September 12, 2009. Published online: November 26, 2009. This work has been supported by the National Institutes of Health (National Institute of General Medical Sciences, R01‐GM57034), Merck Research Laboratories, Novartis, and Boehringer Ingelheim. We thank Evonik for a gift of phosphepine 3 and Dr. Jeffrey H. Simpson (MIT) for assistance with NMR studies.

Attached Files

Supplemental Material - downloadSupplement_doi=10.1002_2Fanie.200905125_file=anie_200905125_sm_miscellaneous_information.pdf

Files

10.1002:anie.200905125-SI.pdf

Files (1.7 MB)

Name Size
md5:7067fd26b11f57ba692c0dcf190903c8
1.7 MB Preview Download

Additional details

Identifiers

Eprint ID
102910
DOI
10.1002/anie.200905125
Resolver ID
CaltechAUTHORS:20200429-135023160

Related works

Describes
10.1002/anie.200905125 (DOI)

Funding

NIH
R01‐GM57034
Merck Research Laboratories
Novartis
Boehringer-Ingelheim

Dates

Created
2020-04-29
Created from EPrint's datestamp field
Updated
2021-11-16
Created from EPrint's last_modified field